Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ecke

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|May 7, 2009
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urotheliumT H Ecke, H Gerullis, P Bartel, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|October 15, 2010
mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a reviewH Gerullis, T H Ecke, C Eimer, et al.
Hefte Zur Unfallheilkunde|January 1, 1979
[Surgical treatment of talus fractures]H Kehr, G Hierholzer, J Kraus, et al.
Anticancer Research|June 25, 2003
Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancerThorsten H Ecke, Severin V Lenk, Horst H Schlechte, et al.
Biomed Research International|April 13, 2017
Evidence in Urologic- and Pelvic-Surgery Research: Finding the IDEAL Way of ReportingH Gerullis, D Barski, P U Malmström, et al.
BJU International|December 15, 2025
Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohortsMatthias May, Anton Kravchuk, Ralph M Wirtz, et al.
Biomedizinische Technik. Biomedical Engineering|January 1, 1990
[Biomechanical analysis of shaft construction of hip endoprostheses]A Bettermann, H Ecke, M Nietert, et al.
Urologie (Heidelberg, Germany)|February 24, 2026
[Report from the 16th annual meeting of the DFBK, 16-17th January 2026 in Ulm]Thorsten H Ecke, Roman Nawroth, Susanne Füssel, et al.
Anti-Cancer Drugs|February 15, 2013
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapyHolger Gerullis, Christoph Eimer, Thorsten H Ecke, et al.
Journal of the Egyptian Society of Parasitology|January 28, 2011
What happens if nothing happens?--History of an untreated urothelial carcinoma of the bladderH Gerullis, T H Ecke, M Wishahi, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|May 7, 2009
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urotheliumT H Ecke, H Gerullis, P Bartel, et al.
Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology|October 15, 2010
mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a reviewH Gerullis, T H Ecke, C Eimer, et al.
Hefte Zur Unfallheilkunde|January 1, 1979
[Surgical treatment of talus fractures]H Kehr, G Hierholzer, J Kraus, et al.
Anticancer Research|June 25, 2003
Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancerThorsten H Ecke, Severin V Lenk, Horst H Schlechte, et al.
Biomed Research International|April 13, 2017
Evidence in Urologic- and Pelvic-Surgery Research: Finding the IDEAL Way of ReportingH Gerullis, D Barski, P U Malmström, et al.
BJU International|December 15, 2025
Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohortsMatthias May, Anton Kravchuk, Ralph M Wirtz, et al.
Biomedizinische Technik. Biomedical Engineering|January 1, 1990
[Biomechanical analysis of shaft construction of hip endoprostheses]A Bettermann, H Ecke, M Nietert, et al.
Urologie (Heidelberg, Germany)|February 24, 2026
[Report from the 16th annual meeting of the DFBK, 16-17th January 2026 in Ulm]Thorsten H Ecke, Roman Nawroth, Susanne Füssel, et al.
Anti-Cancer Drugs|February 15, 2013
Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapyHolger Gerullis, Christoph Eimer, Thorsten H Ecke, et al.
Journal of the Egyptian Society of Parasitology|January 28, 2011
What happens if nothing happens?--History of an untreated urothelial carcinoma of the bladderH Gerullis, T H Ecke, M Wishahi, et al.
Pageof 14